ArticleAsian journal of andrology2013
Prostate cancer risk-associated genetic markers and their potential clinical utility.
Article in Asian journal of andrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Genetic variants within endothelial nitric oxide synthase gene and prostate cancer: a meta-analysis.Clinical and translational science · 2015Pooled it
- Article
- Racial Differences in Prostate Cancer Characteristics and Cancer-Specific Mortality: An Overview.The world journal of men's health · 2022Review
- Inherited risk assessment of prostate cancer: it takes three to do it right.Prostate cancer and prostatic diseases · 2020Review
- Article
- Copy number-based quantification assay for non-invasive detection of PVT1-derived transcripts.PloS one · 2019Article
- Validation of the novel susceptibility loci for prostate cancer in a Chinese population.Oncology letters · 2018Article
- Update on Screening for Urological Malignancies.Rambam Maimonides medical journal · 2017Review
- Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.European urology · 2017Article
- Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.The Prostate · 2016Article
- Article
- Immune Infiltration and Prostate Cancer.Frontiers in oncology · 2015Review
- Polymorphisms influencing prostate-specific antigen concentration may bias genome-wide association studies on prostate cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015Article
- Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes.The Prostate · 2013Article
- Global advances in prostate cancer diagnosis and therapy.Asian journal of andrology · 2013Article
- Mast cells as a potential prognostic marker in prostate cancer.Disease markers · 2013Review
- Association of a common variant at 10q26 and benign prostatic hyperplasia aggressiveness in han chinese descent.Biochemistry research international · 2013Article
- The Xu's chart for prostate biopsy: a visual presentation of the added value of biomarkers to prostate-specific antigen for estimating detection rates of prostate cancer.Asian journal of andrologyArticle
- Prostate cancer antigen 3 and genetic risk score as markers for the detection of prostate cancer in the Chinese population.Asian journal of andrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Prostate cancer (PCa) is one of the most common cancers among men in Western developed countries and its incidence has increased considerably in many other parts of the world, including China. The etiology of PCa is largely unknown but is thought to be multifactorial, where inherited genetics plays an important role. In this article, we first briefly review results from studies of familial aggregation and genetic susceptibility to PCa. We then recap key findings of rare and high-penetrance PCa susceptibility genes from linkage studies in PCa families. We devote a significant portion of this article to summarizing discoveries of common and low-penetrance PCa risk-associated single-nucleotide polymorphisms (SNPs) from genetic association studies in PCa cases and controls, especially those from genome-wide association studies (GWASs). A strong focus of this article is to review the literature on the potential clinical utility of these implicated genetic markers. Most of these published studies described PCa risk estimation using a genetic score derived from multiple risk-associated SNPs and its utility in determining the need for prostate biopsy. Finally, we comment on the newly proposed concept of genetic score; the notion is to treat it as a marker for genetic predisposition, similar to family history, rather than a diagnostic marker to discriminate PCa patients from non-cancer patients. Available evidence to date suggests that genetic score is an objective and better measurement of inherited risk of PCa than family history. Another unique feature of this article is the inclusion of genetic association studies of PCa in Chinese and Japanese populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.